+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
ID07380113

Comparing Anrikefon Injection Versus Oral Nalfurafine Tablets for Sleep Improvement in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus

Led by Zhujiang Hospital · Updated on 2026-08-25

50

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are comparing a new intravenous drug called Anrikefon with a traditional oral medication, nalfurafine orally disintegrating tablets, to see which one improves sleep quality better in patients with chronic kidney disease-associated pruritus CKD-aP. The trial focuses on patients undergoing hemodialysis who have significant itching that affects their sleep. The study also aims to evaluate the safety of Anrikefon alongside its effects on patients quality of life. Participants will be randomly assigned to receive either Anrikefon injection at 0.3 micrograms per kilogram three times per week after dialysis for 4 weeks or nalfurafine tablets at 2.5 micrograms once daily after dinner for 4 weeks. After the treatment period, there will be a 1-week safety follow-up. The trial uses an open-label design, meaning both researchers and participants know which treatment is given. During the study, participants will complete the Pittsburgh Sleep Quality Index to assess sleep improvements and other quality-of-life questionnaires. Researchers will also monitor vital signs, laboratory tests, and adverse events throughout the trial. Secondary measures include itch severity scales, pain thresholds, and blood analyses. The total participation lasts about 5 weeks including treatment and safety follow-up.

CONDITIONS

Brief Title

Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP

Research Team

F

Fengxian Li, DM

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here